Company profile
NexImmune, Inc.
OTC: NEXI · Healthcare · Medical - Pharmaceuticals
#1161 of 1,418 Healthcare companies by revenue
EA Score
——FH —DQ 11GM —SS 14
v0.1 · 25/100 weight · pillars only
↑ balance-sheet leverage, listing tenure · ↓ disclosure history, market scale
Methodology →Revenue TTM
$2.1M
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$32.3M
Employees
6
as of 2026-08-31
Market cap
$139
as of 2026-08-31
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$0$02021
Net income-$32.3M-$32.3M2023
Operating income-$33.0M-$33.0M2023
Total assets$8.6M$8.6M2023
Liabilities$5.1M$5.1M2023
Equity$3.5M$3.5M2023
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is NexImmune, Inc.’s revenue?
NexImmune, Inc. booked $0 in FY2021 revenue — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.
Peers · Healthcare
Thoughtful Brands Inc.——Greenwind Holdings Inc.——Poniard Pharmaceuticals, Inc.——ContraFect Corp.——Heart Tronics, Inc.——Nuvalent, Inc.——Neighbors
Montgomery →Key facts
CEOCraig R. Jalbert
SectorHealthcare
IndustryMedical - Pharmaceuticals
HeadquartersGaithersburg, MD
ExchangeOTC: NEXI
Employees6
IPO date2021-02-12
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.